Conivaptan
As of the edition of 20 October 2026, Conivaptan is a small molecule: marketed, first approved in 2005 (US); acts on AVPR1A and AVPR2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2005
- Kind
- Small molecule
- Brand name
- Vaprisol
- First approved
- 29 December 2005 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Apotex; 2 holders in all
- Registered trials
- 18, 6 stopped early
- Disease areas
- Nutrition and metabolism; Nervous system; Digestive system; Heart and blood vessels; Injuries; Pregnancy and women's health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 3 | 2 | 0 | 1 |
| Phase 3 | 7 | 4 | 0 | 3 |
| Phase 4 | 2 | 1 | 0 | 1 |
| All trials | 18 |